WARRINGTON, Pa., July 23, 2012 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) will report second quarter 2012 results on Thursday, August 2, 2012 before the open of the U.S. financial markets. Discovery Labs will also host a conference call and live webcast at 10:00 a.m. ET that same day to discuss the second quarter financial results and other business matters. A question-and-answer session will follow Discovery Labs' remarks.
To access the conference call and participate in the question and answer session, the number for domestic callers is (866) 332-5218 and for international callers (706) 679-3237. The conference call passcode is 13676514. An audio replay of the conference call will be available until August 10, 2012. The replay number is (855) 859-2056 or (404) 537-3406 using the same conference call password listed above.
The webcast of the conference call will be available on the Company's website at www.discoverylabs.com. It is recommended that participants log onto the webcast at least 15 minutes prior to the call. A replay of the webcast will be available for up to 45 days after the call at the Company's website.
About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to create life-saving products for critical care patients with respiratory disease and improve the standard of care for pulmonary medicine. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide- containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized and aerosolized formulations. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient, targeted upper-respiratory or alveolar delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of such risks and uncertainties are described in Discovery Labs' filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Except as otherwise required by law, Discovery Labs undertakes no obligation to update or revise any forward-looking statements.
CONTACT: John G. Cooper, President and Chief Financial Officer (215) 488-9490